Analgesics - Switzerland | Statista Market Forecast

In Switzerland, the revenue generated in the Analgesics market is estimated to reach US$307.90m by 2024.
It is projected to experience an annual growth rate of 5.14% from 2024 to 2029 (CAGR 2024-2029).
When compared globally, the United States generates the highest revenue in this market, amounting to US$7.24bn in 2024.
In terms of per person revenues, in Switzerland generates approximately US$34.78 per person in 2024.
Switzerland, known for its high quality healthcare system, has seen a growing demand for natural and homeopathic analgesics in the OTC Pharmaceuticals market.

Definition:
The Analgesics market comprises over-the-counter natural and synthetic non-opioid analgesics (only in approved low doses) like Paracetamol, Ibuprofen, Aspirin, Diclofenac and other pain-relieving preparations. Legislation on opioid analgesics differs from country to country. According to the respective state legislation, legal opioid analgesics are included. In Germany, Austria and Switzerland, for instance, opioid analgesics are only included if they are not limited by the narcotics law and do not require prescription. Analgesics are included in the form of pills, capsules, gels and ointments. Not included are prescription medicines (e.g. morphine), anesthetics and homeopathic remedies. Among the top-selling painkillers are Voltaren, Aspirin, Thomapyrin, Ibuprofen, Dolormin, Paracetamol and ASS. It includes both products which are exclusively sold in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

Additional information:
The Analgesics market comprises revenues, average revenue per capita. Sales channels show online and offline revenue. Revenues include VAT. The market only displays B2C revenues, hence B2B and B2G revenues are not included.
For more information on the data displayed, use the info button next to the boxes.

Over-the-counter analgesics (e.g. Aspirin and Paracetamol)
Natural and synthetic agents
In the form of pills, capsules, gels and ointments

Prescription medicines
Homeopathic remedies
Anesthetics

The Analgesics market in Switzerland is experiencing steady growth due to various factors such as customer preferences, market trends, local special circumstances, and underlying macroeconomic factors.

Customer preferences: Swiss customers have shown a growing preference for analgesics due to the increasing awareness about self-care and the importance of managing pain effectively. They are seeking over-the-counter analgesics that provide quick relief from pain and are easily accessible. Additionally, the aging population in Switzerland is driving the demand for analgesics as older individuals often experience chronic pain and seek relief through medication.

Trends in the market: One of the key trends in the Swiss Analgesics market is the growing demand for natural and herbal analgesics. Customers are increasingly opting for products that are perceived as more natural and have fewer side effects. This trend is driven by the rising health consciousness among consumers and their desire for products that align with their wellness goals. As a result, pharmaceutical companies are introducing new analgesic products that contain natural ingredients to cater to this demand.Another trend in the market is the increasing availability of analgesics through online channels. Swiss customers are embracing e-commerce platforms for purchasing analgesics due to the convenience and wide range of options available. This shift towards online purchasing is further supported by the COVID-19 pandemic, which has accelerated the adoption of online shopping across various industries. As a result, pharmaceutical companies are investing in their online presence and partnering with e-commerce platforms to reach a larger customer base.

Local special circumstances: Switzerland has a well-developed healthcare system and a high standard of living, which contributes to the growth of the Analgesics market. The country has a strong pharmaceutical industry and is known for its high-quality healthcare products. Swiss customers have trust in locally manufactured analgesics and are willing to pay a premium for products that are perceived as being of superior quality. This local preference for Swiss-made analgesics creates opportunities for domestic pharmaceutical companies to thrive in the market.

Underlying macroeconomic factors: The Swiss economy has been relatively stable, with a high per capita income and low unemployment rates. This favorable economic environment has a positive impact on the Analgesics market as customers have the financial means to purchase analgesics. Additionally, the Swiss government has a strong focus on healthcare and provides comprehensive healthcare coverage to its citizens. This ensures that individuals have access to necessary medications, including analgesics, which further boosts the market demand.In conclusion, the Analgesics market in Switzerland is experiencing growth driven by customer preferences for quick relief and natural products, the trend of online purchasing, the local preference for Swiss-made analgesics, and the favorable macroeconomic factors. Pharmaceutical companies operating in this market can capitalize on these trends and cater to the evolving needs of Swiss customers.

Data coverage:

Data encompasses B2C spend. Figures are based on the OTC Pharmaceuticals market values, representing revenues generated by both product sales which take place exclusively in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use data from national statistical offices, international institutions, trade associations, and self-medication associations. Next, we use relevant key market indicators and data from country-specific associations, such as consumer healthcare spending, out-of-pocket healthcare expenditure, health system accessibilities, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. Whereas this market covers only OTC drugs, the Statista Pharmaceuticals market covers both OTC and prescription drugs.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.